1. Introduction {#sec1}
===============

The name of*Bulsu-san* (BSS) originated from its therapeutic effects that help to promote easy labor as if being touched by merciful Buddha\'s hand \[[@B1]\]. BSS is composed of*Angelicae Sinensis* Radix (Danggui, DG) and*Cnidium officinale* Makino (Cheongung, CG), which is one of the most commonly used herb pairs in Traditional Medicine of East Asia and the usual component ratio is 2 : 3 (CG : DG) or 1 : 1 \[[@B2]\]. BSS is widely used in women\'s medicine in East Asia; its recognized therapeutic effects are as follows: removal of impure blood, blood making, easy parturition, acceleration of labor, elimination of dead fetus or placenta, amelioration of pain, nourishing blood, and promoting blood circulation \[[@B3]\].

What is more, recent experimental research on the CG-DG herb pair indicated that they affect the nourishment of blood \[[@B4]\], activate blood circulation, and prevent blood stasis \[[@B5]\]. In addition, the CG-DG herb pair showed significant inhibitory effects on the proliferation and protein synthesis of vascular smooth muscle cells \[[@B6]\]. It was suggested BSS could affect the activities of Akt kinase and eNOS by increasing intracellular Ca^2+^ and reducing ROS levels \[[@B7]\] and regulate menstruation and provide relief from pain by enabling the management of uterine smooth muscle contractions \[[@B8]\]. Although BSS has therapeutic effects on various pathological symptoms in pregnant or childbearing aged women, this research focused on the molecular mechanisms and impact of BSS on easing parturition and the acceleration of labor.

In terms of parturition onset, numerous studies have described the complex hormone interactions between estrogen, progesterone, oxytocin, corticosteroid, and prostaglandin. Among these, corticotrophin releasing hormone (CRH) is regarded as a trigger that initiates the labor \[[@B9]\]. The placenta releases substantial amounts of CRH, which stimulates the pituitary glands of both mother and fetus to secrete adrenocorticotropin hormone \[[@B10]\]. This in turn induces the release of estrogen precursor, which is converted into estrogen by the placenta that induces smooth muscle contraction \[[@B10]\]. Additionally, dilatation of cervical connective tissue and smooth muscle is induced by the following changes: a shift from progesterone to estrogen dominance, increased responsiveness to oxytocin via the upregulation of myometrial oxytocin receptor, increased prostaglandins synthesis in uterus, increased myometrial gap junction formation, decreased nitric oxide activity, and increased influx of calcium into myocyte \[[@B11]\].

The hypothesis of this study was that BSS may promote the positive-feedback of hormone loops as well as a series of myometrial and cervical changes to ease parturition and safely accelerate labor. A network based in silico approach was used to identify the effect of BSS on parturition related systems and the aim of this study was to elucidate the effect of BSS on the parturition by system-level analysis. The workflow of the network pharmacological study is summarized in [Figure 1](#fig1){ref-type="fig"}.

2. Material and Methods {#sec2}
=======================

2.1. Identification of Active Compounds {#sec2.1}
---------------------------------------

Compounds in CG and DG were identified using a phytochemical database that is the Traditional Chinese Medicine Systems Pharmacology (TCMSP, <http://ibts.hkbu.edu.hk/LSP/tcmsp.php>). We applied parameters related to absorption, distribution, metabolism, and excretion (ADME), namely, human drug-likeness (DL) \[[@B12]\], oral bioavailability (OB) \[[@B13]\], and Caco-2 permeability (Caco-2) to screen the Potential active compounds in BSS \[[@B14]\].

### 2.1.1. Drug-Likeness Evaluation {#sec2.1.1}

DL helps filter "drug-like" compounds in oriental herbs, as DL represents a qualitative concept for valuations based on how "drug-like" a prospective compound is \[[@B15]\]. Accordingly, a high DL may lead to a greater possibility of therapeutic success, and compounds with a higher DL value are more likely to possess certain biological properties \[[@B16]\]. The calculations of DL in TCMSP database were based on Tanimoto coefficient formula \[[@B17]\] as follows:$$\begin{matrix}
{F\left( { A,B} \right) = \frac{A \times B}{A^{2} + B^{2} - A \times B},} \\
\end{matrix}$$where *A* represents the molecular parameters of herbal compounds and *B* is the average molecular parameters of all compounds in the Drugbank database (<http://www.drugbank.ca/>) \[[@B18]\]. In the present study, we excluded compounds with a DL of \<0.08. Other previous researches of herbal formulas set a higher threshold in the range of 0.1 to 0.18. However, we found out that most compounds of DG have low DL. In detail, only 36 compounds of 125 in DG show higher or equal DL value than 0.08. For this reason, this study sets a lower threshold of DL than other previous researches to see the most potential targets of BSS.

### 2.1.2. Oral Bioavailability (OB) Prediction {#sec2.1.2}

OB is defined as the ratio of active compounds\' absorption into the systemic circulation, which represents the convergence of the ADME process \[[@B13]\]. OB values are dependent on drug dissolution in the gastrointestinal (GI) tract and hepatic and intestinal first-pass metabolism, as well as on intestinal membrane permeation, which makes it a major pharmacokinetic parameter for drug evaluations \[[@B16]\]. In this study, the OB threshold was set as ≥15%.

### 2.1.3. Caco-2 Permeability Screening {#sec2.1.3}

Caco-2 permeability is used to predict the absorption of an orally administered drug \[[@B14]\]. Surface absorptivity of the small intestine is maximized with the presence of villi and microvilli, for this reason most orally administered drug absorption occurs in the small intestine \[[@B19]\]. Moreover, the movement of orally administered drugs across the intestinal epithelial barrier determines the rate and extent of human absorption and ultimately affects drug bioavailability \[[@B20]\]. In the present study, compounds with OB, DL and Caco-2 values of greater than 15%, 0.08, and \>−0.4, respectively, were regarded as active compounds and subjected to further analysis.

### 2.1.4. Lipinski\'s Rule (LR) Screening {#sec2.1.4}

In addition, the screening standard used was defined based on Lipinski\'s rule (LR), which identifies druggable compounds as having molecular weight (MW) of ≤500 Da (MW ≤ 500), chemical composition with ≤5 hydrogen-bond donors, ≤10 hydrogen-bond acceptors, and an octanol-water partition coefficient, AlogP of ≤ 5 \[[@B21]\]. AlogP can be used to estimate local hydrophobicity, to produce molecular hydrophobicity maps, and to evaluate hydrophobic interactions in protein-ligand complexes \[[@B22]\]. Hdon and Hacc are the number of possible hydrogen-bond donors and acceptors, and the hydrogen-bonding capacity of a drug solute is recognized as a crucial determinant of permeability; moreover high hydrogen-bonding potential is often related to low permeability and absorption \[[@B23]\]. Eventually, in the present study, we selected active compounds satisfying the following criteria: OB ≥ 15%; DL ≥ 0.08; Caco-2 ≥ −0.4; MW ≤ 500; H-bond donors ≤ 5; H-bond acceptors ≤ 10; AlogP ≤ 5.

2.2. Target Fishing {#sec2.2}
-------------------

Aside from filtering active compounds, we also sought to identify the molecular targets of these active compounds. Compound-target interaction profiles were established based on a systematic prediction of multiple drug-target interactions tool which employs random forest (RF) and support vector machine (SVM) methods and integrates chemical, genomic, and pharmacological information for drug targeting and discovery on a large scale \[[@B24]\]. Compound-target interactions satisfying SVM score ≥ 0.8 and RF score ≥ 0.7 were selected for further study. Additionally, filtered compound-target interaction profile mapping was performed using the UniProt database (<http://www.uniprot.org/>) \[[@B25]\].

2.3. Gene Ontology (GO) Analysis {#sec2.3}
--------------------------------

Biological process (BP) of gene ontology (GO) analysis was employed to determine the biological properties of target genes \[[@B26]\]. GO annotation indicates the possibility of direct statistical analysis on gene function information. In this research, GO BP terms with *P* values \< 0.01 were employed and the data was collected using the DAVID 6.8 Gene Functional Classification Tool (<http://david.abcc.ncifcrf.gov/>).

2.4. Network Construction and Analysis {#sec2.4}
--------------------------------------

In order to understand the multiscale interactions between the active compounds of BSS and targets, two types of networks were built: (1) the herb-compound-target network (H-C-T network), in which nodes represent either compounds, target genes, or herbs and edges indicate herb-compound-target connections; and (2) the target-pathway network (T-P network) to extract the pathways from KEGG database (<http://www.genome.jp/kegg/>), and the terms highly associated with parturition with *P* values \< 0.05 were selected as the related pathways of targets in this work. Related targets were mapped onto relevant pathways, which resulted in the T-P network. Both networks were generated in Cytoscape 3.5.1, an open-source biological network visualization and data integration software package \[[@B27]\].

2.5. Target Organ Location Map {#sec2.5}
------------------------------

Tissue-specific patterns of mRNA expression can indicate important associations with biological events or gene functions \[[@B28]\]. To explore the beneficial effects of BSS during parturition, it is important that the tissue mRNA expression profiles of target genes at the organ level be known \[[@B29]\]. The target organ location map was built according to the Dataset: GeneAtlas U133A, gcrma (<http://biogps.org>). BioGPS database provides expression data acquired by direct measurements of gene expression obtained by microarrays analysis \[[@B30]\]. First, the mRNA expression patterns of each target gene in 176 parts of organ tissues were obtained. Second, average values were calculated for each gene. Third, frequency of above average mRNA expression tissue organs was inspected. Forth, based on the result from the third step and parturition mechanism theory, mRNA expression data of relevant organ tissues were extracted and categorized into 6 groups, namely, uterus and/or uterus corpus, fetus and/or placenta, hypothalamus and/or pituitary, smooth muscle, and whole blood.

3. Results {#sec3}
==========

3.1. Identification of Active Compounds {#sec3.1}
---------------------------------------

314 compounds of BSS were identified, including 189 molecules in CG and 125 in DG (as shown in Supplementary Material Table S1 in Supplementary Material available online at <https://doi.org/10.1155/2017/7236436>) and active compounds met the criteria OB ≥ 15%, Caco-2 ≥ −0.4, and DL ≥ 0.08, as well as the standards of Lipinski\'s rule (LR) (as shown in [Table 1](#tab1){ref-type="table"}). In detail, 60 active compounds were initially chosen, but 8 compounds were present in both herbs, namely, 3-butylidene-7-hydroxyphthalide, adenine, BdPh, beta-selinene, palmitic acid, senkyunolide-C, senkyunolide-D, and senkyunolide-E, and 14 had no target protein information and were thus excluded from the list of active compounds, whereas 27 compounds with lower ADME properties than above thresholds were included, which were reported to be related to oxytocin. In total, 65 active compounds were filtered.

Although ligustilide and ferulic acid have a DL of \<0.08, both were included in this study. Since ligustilide (C12, DL = 0.07, OB = 53.72, Caco-2 = 1.3) was reported to be the main compound of DG in uterine contraction \[[@B31]\], and ferulic acid (C42, DL = 0.06, OB = 54.97, Caco-2 = 0.53) has been reported to be useful for the treatment of vascular diseases \[[@B6], [@B32]\] and blood deficiency syndrome \[[@B33]\] in China and to suppress inflammatory responses and tumor progression \[[@B34]\]. Some other compounds also have been shown experimentally to have various biological activities; for example, crysophanol (C42, DL = 0.21, OB = 18.64, Caco-2 = 0.62) can be used to treat menorrhagia and thrombocytopenia \[[@B35]\]. Perlolyrine (C52, DL = 0.27, OB = 65.95, Caco-2 = 0.88) was confirmed to have a protective effect on injured human umbilical vein endothelial cells \[[@B36]\], and myricanone (C48, DL = 0.51, OB = 57.61, Caco-2 = 0.67) was found to best inhibit mouse skin tumor progression \[[@B37]\].

3.2. Target Fishing {#sec3.2}
-------------------

The 65 active compounds interact with 185 target proteins, as shown in [Table 2](#tab2){ref-type="table"}; in other words, on average, each compound on average interacts with 2.85 target proteins. This result confirms the polypharmacological character of oriental medicine and demonstrates the synergistic effects of multiple compounds on multiple targets \[[@B38]\]. Different compounds in CG and DG can directly affect common targets, for example, the target protein "calmodulin (CALM1)" interacts with crysophanol from CG and coniferyl ferulate from DG at the same time, which implies the synergetic or cumulative effects of herbal medicine.

3.3. GO Analysis {#sec3.3}
----------------

397 biological process terms with *P* values of \<0.01 were sorted using the functional annotation chart of the DAVID 6.8 Gene Functional Classification Tool, based on 185 filtered target genes, and *P* values were adjusted using the Benjamini-Hochberg method. 30 enriched GO BP terms extracted by *P* value and gene counts are displayed in [Figure 2](#fig2){ref-type="fig"}. It is meaningful that most of the target genes are significantly related to the various BP involved in parturition. For instance, 30 extracted GO BP terms include "MAPK signaling pathways," "steroid hormone mediated signaling pathway," "response to glucocorticoid," "response to estradiol," and "positive regulation of ERK1 and ERK2 cascade." "MAPK signaling pathways" were reported to be activated in human uterine cervical ripening during parturition \[[@B39]\]. "Steroid hormone mediated signaling pathway" is highly related to parturition process as estrogen and progesterone play important roles in pregnancy and parturition, and estrogen induceS the principal stimulatory myometrial contractility \[[@B40]\]. Also, estradiol takes key place in parturition process \[[@B41]\]. It was identified that increased ERK activation is observed at the onset of labor, and it promotes myometrial contractility and development of parturition \[[@B42], [@B43]\]. To sum up, the target genes of BSS are highly associated with the biological process (BP) of parturition.

3.4. Network Construction and Analysis {#sec3.4}
--------------------------------------

Network analysis is an efficient tool for visualizing and understanding multiple targeted drug actions and demonstrates drug actions within the context of the whole genome \[[@B44], [@B45]\]. For a better insight of therapeutic impacts, H-C-T and T-P networks were constructed and displayed in Figures [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}, respectively. In the H-C-T network, nodes represent herb names, compounds, and targets. Also in the T-P network, circular nodes represent targets and triangle nodes represent pathways. Besides node size is relative to the degree and edges show interactions between nodes.

H-C-T network confirmed that there were 739 interactions between 185 targets and 65 active compounds of CG and DG: oleic acid (C48, degree = 42) with the highest number of interactions with targets, followed by succinic acid (C63, degree = 40) and stigmasterol (C62, degree = 37). It shows that single molecules target multiple receptors \[[@B46]\]. Also, some compounds from CG and DG were found to share common targets. Likewise, prostaglandin G/H synthase 2 (PTGS2, degree = 56) displayed the most affinitive connections with compounds, followed by gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1, degree = 48), prostaglandin G/H synthase 1 (PTGS1, degree = 37), and muscarinic acetylcholine receptor M1 (CHRM1, degree = 37). Except for C60 (PLA2G1B, degree = 1), the rest of the 64 active compounds are connected with more than one target; likewise, 73 (39.5%) target genes out of 185 interacted with more than one compound. This result demonstrates the multicompounds and multitarget properties of herbal compounds and there was a report that compounds with multiple targets could have greater therapeutic efficacy \[[@B47]\].

In addition, the top 40 pathways were extracted based on gene counts and *P* value (\<0.05), and *P* value was adjusted by Benjamini-Hochberg method. T-P network using relevant targets of herbal compounds is demonstrated in [Figure 4](#fig4){ref-type="fig"}. There were 485 interactions between the top 40 pathways and 135 of 185 target genes. "Metabolic pathways" (degree = 49) and "neuroactive ligand-receptor interaction pathway" (degree = 32) had the highest and the second highest numbers of connections with the targets, followed by "calcium signaling" (degree = 21), "cAMP signaling pathway" (degree = 17), and "cGMP PKG signaling pathway" (degree = 15). These are compelling results that parturition processes are the complex hormone interactions and it is well known that calcium signals within the myometrium are pivotal for uterine contractions \[[@B48]\]. In the same manner, some target genes demonstrated higher degree centrality with top 40 pathways, namely, PI3-kinase subunit gamma (PIK3CG, degree = 23), cAMP-dependent protein kinase catalytic subunit alpha (PRKACA, degree = 20), protein kinase C beta type (PRKCB, degree = 18), and calmodulin (CALM1, degree = 11). We can confirm the same result in the previous researches. For instance, PI3-kinase subunit gamma plays the key role in regulating cAMP, calcium cycling, and beta-adrenergic signaling \[[@B49]\]. Moreover, during the labor, calmodulin-calcium complex activates myosin light-chain kinase, which causes the generation of ATPase activity; eventually, uterine contraction is promoted \[[@B50]\].

H-C-T network explains the multitarget, multicompounds properties and accumulates effect of herbal medicines and T-P network shows that target genes of BSS are highly related to the pathway associated with parturition process.

3.5. Target Organ Location Map {#sec3.5}
------------------------------

It is important to confirm the tissue mRNA expression profiles of the target genes at the organ level to identify the effects of BSS on parturition. Since there was no mRNA expression information in BioGPS of muscarinic acetylcholine receptor M1 (CHRM1), putative beta-glucuronidase-like protein SMA3 (GUSBP1), and retinol-binding protein 2 (RBP2), excluding these 3 targets from 185 filtered targets, totally 182 genes mRNA expression profiles were analyzed in this study. There were 519 interactions between target genes and organ locations. The networks of target genes tissue mRNA expression profiles and compounds of BSS are shown in [Figure 5](#fig5){ref-type="fig"}.

As a result, 159 of 182 target genes displayed beyond average mRNA expression in relevant organ tissues, such as uterus and/or uterus corpus, fetus and/or placenta, hypothalamus and/or pituitary, smooth muscle, and whole blood. The rest of 23 genes of 182 targets did not display above average mRNA expression in above organ tissues, for example, gamma-aminobutyric acid receptor subunit alpha-6 (GABRA6) and coagulation factor X (F10).

Nevertheless, most genes of 159 demonstrated high expression patterns in several organs of parturition related tissues at the same time. In detail, 60 genes showed most significant mRNA expression in the uterus and/or uterus corpus group, 130 for placenta and/or fetus, 86 for hypothalamus and/or pituitary, 82 for smooth muscle, 80 for pituitary, and 81 for whole blood. Besides, 30 of 159 genes showed expression in all of 6 groups. For instance, muscarinic acetylcholine receptor M2 (CHRM2), neuronal acetylcholine receptor subunit *α*-2 (CHRNA2), gamma-aminobutyric acid receptor subunit alpha-3 (GABRA3), NO synthase, inducible (NOS2), cGMP-inhibited 3′,5′-cyclic phosphodiesterase A (PDE3A), and sodium-dependent dopamine transporter (SLC6A3) recorded beyond average mRNA expression in all six groups. Furthermore, 79% of targets were expressed in two or more organ tissues, which suggests that those organs and target genes of BSS are closely correlated.

4. Discussion {#sec4}
=============

In this study, network pharmacology method with DL, OB, Caco-2, and LR evaluation, multiple drug-target prediction, network analysis, and relevant organ location mapping was used to explain the targets of BSS in relation to the parturition process. There is no denying that network based analysis is powerful approach for identifying the actions of multitargeting herbal medicines at the systems level and our study shows target genes of BSS are strongly connected to parturition related pathways, biological processes, and organs. It was confirmed that 98% of the active compounds of BSS were interacted with more than two targets and 39.5% of the targets related to more than one compound. The synergetic multitarget properties of BSS were visualized, but further discussion about differentiated drug action based on degree centrality and simultaneous targeting effect of more than one compound is required \[[@B51]\]. Also, detailed potential pathways of BSS should be explored deeply in the future.

Similar findings were identified in a few RCT researches in China that using BSS in induction of labor can reduce the delivery time, the amount of bleeding, and the residual rate of placenta \[[@B52], [@B53]\]. In addition, BSS targets six genes of GABA receptor and NOS, which was reported to be related oxytocin neurons at the time of parturition in rats \[[@B54]\]. Also, BSS targets NOS and NO (nitric oxide) which are involved in the regulation of uterine contractility during pregnancy and is a key factor for the onset of labor \[[@B55]\], and iNOS (inducible nitric oxide synthase) can be upregulated accordantly by similar inflammatory mediators during ripening \[[@B11]\].

In fact, rather than DG,*Angelicae Gigantis Radix* (Danggwi, AGR) grows naturally in Korea; for that reason, the combination of AGR and CG is commonly used as BSS in Korea. Instead, DG is named as Chinese Danggwi for accurate classification in Korea. Several studies have shown AGR is differs from DG in terms of its main active constituents and genetic form. AGR is mainly composed of water soluble polysaccharide but coumarin, which is liposoluble including nodakenin (1), peucedanone (2), marmesin (3), decursinol (4), 7-hydroxy-6-(2R-hydroxy-3-methylbut-3-enyl) coumarin (5), demethylsuberosin (6), decursin (7), decursinol angelate (8), and isoimperatorin (9) \[[@B56]\]. Of these, decursin and its isomer decursinol angelate have been reported to be the active compounds in AGR \[[@B57]\]. It was identified in the experimental studies that AGR and DG act via different mechanisms in the cardiovascular, central nervous system, and anticancer activity but both have similar pharmacological effects \[[@B57]\]. Since the compositions of DG and AGR differ, further study on BSS with AGR is required. Currently, BSS is commonly prescribed to treat cerebra vascular and cardiovascular diseases in China \[[@B33]\], but, in Korea, BSS is widely applied in obstetrics.

The similarity between cervical ripening during parturition and inflammatory reaction has been pointed out in earlier studies; this has been attributed to the induction of leukocyte migration into tissue, thus promoting cervical remodeling and parturition by estrogen \[[@B59]\]. Further study is needed in terms of the effect of BSS on inflammatory reactions and parturition.

Furthermore, the CG-DG herb pair has other names, such as, Gunggui-tang (weight ratios of 2 : 3 or 1 : 1), Ogeum-san (1 : 1), Iphyo-san (1 : 1), and Sinmyo Bulsu-san (1 : 2), those are prepared at different weight ratios \[[@B3]\]. Accordingly, weight ratio should be determined based on considerations of targeted symptoms for relevant clinical applications.

5. Conclusion {#sec5}
=============

This study results show that*Bulsu-san* (BSS) is highly connected to the parturition related pathways, biological processes, and organs. Most compounds in BSS work together with multiple target genes in a synergetic way, and this was confirmed using herb-compound-target network and target-pathway network analysis. The mRNA expression of relevant target genes of BSS was elevated significantly in parturition related organ tissues, such as those of the uterus, placenta, fetus, hypothalamus, and pituitary gland.

This study employed the network analytical methods to show the multicompound, multitarget properties of BSS. The results not only support clinical applications of BSS on easing childbirth but also suggest the related target genes and pathways of BSS on promoting parturition according to a systems-level in silico analytic approach. However, detailed mechanisms and other functions of BSS should be discussed further.
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Table S1: 314 Compounds of BSS (189 molecules of CG and 125 of DG).
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![The workflow: the network pharmacological approach of Bulsu-san (BSS), namely, active compounds screening, target fishing, network analysis, and relevant organ location mapping was performed in this study.](ECAM2017-7236436.001){#fig1}

![GO analysis: 30 enriched biological process (BP) of gene ontology (GO) terms sorted by *P* value \< 0.01 and gene counts are displayed. The *y*-axis represents enriched biological process (BP) terms for the target genes, and the *x*-axis shows gene counts and −log⁡10 (*P* value).](ECAM2017-7236436.002){#fig2}

![H-C-T network: herb-compound-target (H-C-T) network demonstrated multicompound, multitarget property of BSS. In this network, red and blue nodes represent herbs, green nodes show compounds, and pink nodes indicate targets and node size is relative to the degree and edges demonstrate interactions between nodes.](ECAM2017-7236436.003){#fig3}

![T-P network: in target-pathway (T-P) network, circular nodes represent compounds and triangles indicate pathways. Node size is relative to the degree and edges demonstrate interactions between nodes.](ECAM2017-7236436.004){#fig4}

![Target organ location map: it shows that tissue-specific patterns of mRNA expression are highly active in relative organs of parturition process such as uterus, fetus, placenta, hypothalamus, pituitary, and smooth muscle. Yellow nodes show compounds and pink nodes indicate targets and node size is relative to the degree and edges demonstrate interactions between nodes.](ECAM2017-7236436.005){#fig5}

###### 

65 Potential active compounds of BSS (compound with *∗* was present in both herbs).

  ID         Active compounds                                                                                                    OB (%)   Caco-2   DL     Herb
  ---------- ------------------------------------------------------------------------------------------------------------------- -------- -------- ------ -------
  C1         ()-alpha-Terpineol                                                                                                  46.3     1.28     0.03   DG
  C2         ()-Aromadendrene                                                                                                    55.74    1.81     0.1    CG
  C3         ()-Terpinen-4-ol                                                                                                    81.41    1.36     0.03   CG
  C4         (+)-alpha-Funebrene                                                                                                 52.87    1.79     0.1    CG
  C5         (+)-Ledol                                                                                                           16.96    1.43     0.12   DG
  C6         (1R,5R,7S)-4,7-Dimethyl-7-(4-methylpent-3-enyl)bicyclo\[3.1.1\]hept-3-ene                                           16.23    1.86     0.09   CG
  C7         (1S,4aR,8aR)-1-Isopropyl-7-methyl-4-methylene-2,3,4a,5,6,8a-hexahydro-1H-naphthalene                                19.8     1.86     0.08   DG
  C8         (1S,4E,8E,10R)-4,8,11,11-tetramethylbicyclo\[8.1.0\]undeca-4,8-diene                                                21.69    1.86     0.08   CG
  C9         (3E)-3-butylidene-7-hydroxy-2-benzofuran-1-one                                                                      42.17    1.03     0.08   DG
  C10        (L)-alpha-Terpineol                                                                                                 48.8     1.39     0.03   CG
  C11        (R)-Linalool                                                                                                        39.8     1.33     0.02   CG
  C12        (Z)-Ligustilide                                                                                                     53.72    1.3      0.07   CG
  C13        1-Acetyl-beta-carboline                                                                                             67.12    1.18     0.13   CG
  C14        1-beta-Ethylacrylate-7-aldehyde-beta-carboline                                                                      28.53    0.45     0.31   CG
  C15        1H-Cycloprop(e)azulen-7-ol, decahydro-1,1,7-trimethyl-4-methylene-, (1aR-(1aalpha,4aalpha,7beta,7abeta,7balpha))-   82.33    1.37     0.12   CG
  C16        1-Terpineol                                                                                                         49.83    1.24     0.03   CG
  C17        2,6-Di(phenyl)thiopyran-4-thione                                                                                    69.13    1.74     0.15   DG
  C18        2-\[(2S,5S,6S)-6,10-Dimethylspiro\[4.5\]dec-9-en-2-yl\]propan-2-ol                                                  37.62    1.44     0.09   CG
  C19^*∗*^   3-Butylidene-7-hydroxyphthalide                                                                                     62.68    1        0.08   CG&DG
  C20        4,7-Dihydroxy-3-butylphthalide                                                                                      106.09   0.69     0.1    CG
  C21        49070_FLUKA                                                                                                         85.51    1.29     0.12   CG
  C22        4-Hydroxy-3-butylphthalide                                                                                          70.31    0.9      0.08   CG
  C23        58870_FLUKA                                                                                                         49.01    1.82     0.1    CG
  C24^*∗*^   Adenine                                                                                                             62.81    −0.3     0.03   CG&DG
  C25        ADO                                                                                                                 15.98    −1.56    0.18   CG
  C26        alpha-Cubebene                                                                                                      16.73    1.83     0.11   CG
  C27        alpha-Selinene                                                                                                      31.81    1.82     0.1    CG
  C28        Aromadendrene oxide 2                                                                                               65.1     1.56     0.14   CG
  C29^*∗*^   BdPh                                                                                                                42.44    1.32     0.07   CG&DG
  C30        beta-Chamigrene                                                                                                     31.99    1.82     0.08   DG
  C31^*∗*^   beta-Selinene                                                                                                       24.39    1.83     0.08   CG&DG
  C32        beta-Cubebene                                                                                                       32.16    1.82     0.11   CG
  C33        Cadinene                                                                                                            17.12    1.88     0.08   DG
  C34        Caffeic acid                                                                                                        25.76    0.21     0.05   CG
  C35        Carotol                                                                                                             149.03   1.46     0.09   CG
  C36        Cedrene                                                                                                             51.14    1.82     0.11   CG
  C37        Chuanxiongol                                                                                                        22.19    0.94     0.1    CG
  C38        cis-Thujopsene                                                                                                      56.43    1.84     0.12   DG
  C39        Coniferyl ferulate                                                                                                  4.54     0.71     0.39   DG
  C40        Crysophanol                                                                                                         18.64    0.62     0.21   CG
  C41        FA                                                                                                                  68.96    −1.5     0.71   CG
  C42        Ferulic acid (CIS)                                                                                                  54.97    0.53     0.06   DG
  C43        InChI=1/C15H24/c1-10-7-8-15-9-12(10)14(3,4)13(15)6-5-11(15)2/h7,11-13H,5-6,8-9H2,1-4H                               55.56    1.79     0.1    DG
  C44        L-Bornyl acetate                                                                                                    65.52    1.29     0.08   CG
  C45        Methyl palmitate                                                                                                    18.09    1.37     0.12   CG
  C46        Myricanone                                                                                                          40.6     0.67     0.51   CG
  C47        Nicotinic acid                                                                                                      47.65    0.34     0.02   DG
  C48        Oleic acid                                                                                                          33.13    1.17     0.14   CG
  C49^*∗*^   Palmitic acid                                                                                                       19.3     1.09     0.1    CG&DG
  C50        Perlolyrine                                                                                                         65.95    0.88     0.27   CG
  C51        PLO                                                                                                                 14.07    0.69     0.43   CG
  C52        Scopoletol                                                                                                          27.77    0.71     0.08   DG
  C53        Senkyunolide A                                                                                                      26.56    1.3      0.07   CG
  C54        Senkyunolide G                                                                                                      39.52    0.63     0.08   CG
  C55^*∗*^   Senkyunolide-C                                                                                                      46.8     0.87     0.08   CG&DG
  C56^*∗*^   Senkyunolide-D                                                                                                      79.13    0.12     0.1    CG&DG
  C57^*∗*^   Senkyunolide-E                                                                                                      34.4     0.55     0.08   CG&DG
  C58        Senkyunolide-K                                                                                                      61.75    0.52     0.08   CG
  C59        Sinapic acid                                                                                                        64.15    0.48     0.08   CG
  C60        Sphingomyelin                                                                                                       0.31     −0.46    0.51   DG
  C61        Stearic acid                                                                                                        17.83    1.15     0.14   CG
  C62        Stigmasterol                                                                                                        43.83    1.44     0.76   DG
  C63        Succinic acid                                                                                                       29.62    −0.44    0.01   DG
  C64        Sucrose                                                                                                             7.17     −2.89    0.23   CG
  C65        Wallichilide                                                                                                        42.31    0.82     0.71   CG

###### 

Related targets of potential compounds in BSS.

  UniProt ID   Target name                                                                                            Gene Name
  ------------ ------------------------------------------------------------------------------------------------------ -----------
  P80404       4-aminobutyrate aminotransferase, mitochondrial                                                        ABAT
  P33121       Long-chain-fatty-acid-* *-CoA ligase 1                                                                 ACSL1
  O60488       Long-chain-fatty-acid-* *-CoA ligase 4                                                                 ACSL4
  P00813       Adenosine deaminase                                                                                    ADA
  P07327       Alcohol dehydrogenase 1A                                                                               ADH1A
  P00325       Alcohol dehydrogenase 1B                                                                               ADH1B
  P00326       Alcohol dehydrogenase 1C                                                                               ADH1C
  P29274       Adenosine A2a receptor                                                                                 ADORA2A
  P35348       Alpha-1A adrenergic receptor                                                                           ADRA1A
  P35368       Alpha-1B adrenergic receptor                                                                           ADRA1B
  P25100       Alpha-1D adrenergic receptor                                                                           ADRA1D
  P08913       Alpha-2A adrenergic receptor                                                                           ADRA2A
  P18089       Alpha-2B adrenergic receptor                                                                           ADRA2B
  P18825       Alpha-2C adrenergic receptor                                                                           ADRA2C
  P08588       Beta-1 adrenergic receptor                                                                             ADRB1
  P07550       Beta-2 adrenergic receptor                                                                             ADRB2
  Q5SY84       Adenylosuccinate synthetase                                                                            ADSS
  P21549       Serine-* *-pyruvate aminotransferase                                                                   AGXT
  O43865       Putative adenosylhomocysteinase 2                                                                      AHCYL1
  P15121       Aldose reductase                                                                                       AKR1B1
  P13716       Delta-aminolevulinic acid dehydratase                                                                  ALAD
  P51649       Succinate semialdehyde dehydrogenase, mitochondrial                                                    ALDH5A1
  P04745       Alpha-amylase 1                                                                                        AMY1A
  P04746       Pancreatic alpha-amylase                                                                               AMY2A
  P04114       Apolipoprotein B-100                                                                                   APOB
  P10275       Androgen receptor                                                                                      AR
  P06576       ATP synthase subunit beta, mitochondrial                                                               ATP5B
  P06276       Cholinesterase                                                                                         BCHE
  P10415       Apoptosis regulator Bcl-2                                                                              BCL2
  Q06187       Tyrosine-protein kinase BTK                                                                            BTK
  P00915       Carbonic anhydrase I                                                                                   CA1
  P62158       Calmodulin                                                                                             CALM1
  P42574       Caspase-3                                                                                              CASP3
  P04040       Catalase                                                                                               CAT
  P06307       Cholecystokinin                                                                                        CCK
  P20248       Cyclin-A2                                                                                              CCNA2
  P30305       M-phase inducer phosphatase 2                                                                          CDC25B
  P24941       Cell division protein kinase 2                                                                         CDK2
  P11597       Cholesteryl ester transfer protein                                                                     CETP
  P28329       Choline O-acetyltransferase                                                                            CHAT
  O14757       Serine/threonine-protein kinase Chk1                                                                   CHEK1
  P36222       Chitinase-3-like protein 1                                                                             CHI3L1
  P11229       Muscarinic acetylcholine receptor M1                                                                   CHRM1
  P08172       Muscarinic acetylcholine receptor M2                                                                   CHRM2
  P20309       Muscarinic acetylcholine receptor M3                                                                   CHRM3
  Q15822       Neuronal acetylcholine receptor subunit alpha-2                                                        CHRNA2
  P36544       Neuronal acetylcholine receptor protein, alpha-7 chain                                                 CHRNA7
  Q99966       Cbp/p300-interacting transactivator 1                                                                  CITED1
  P02452       Collagen alpha-1(I) chain                                                                              COL1A1
  Q02388       Collagen alpha-1(VII) chain                                                                            COL7A1
  P17538       Chymotrypsinogen B                                                                                     CTRB1
  P07339       Cathepsin D                                                                                            CTSD
  P04798       Cytochrome P450 1A1                                                                                    CYP1A1
  P05177       Cytochrome P450 1A2                                                                                    CYP1A2
  Q9ULA0       Aspartyl aminopeptidase                                                                                DNPEP
  P27487       Dipeptidyl peptidase IV                                                                                DPP4
  P21728       Dopamine D1 receptor                                                                                   DRD1
  P14416       D(2) dopamine receptor                                                                                 DRD2
  P25101       Endothelin-1                                                                                           EDNRA
  Q07075       Glutamyl aminopeptidase                                                                                ENPEP
  Q6UWV6       Ectonucleotide pyrophosphatase/phosphodiesterase family member 7                                       ENPP7
  P04626       Receptor tyrosine-protein kinase erbB-2                                                                ERBB2
  P03372       Estrogen receptor                                                                                      ESR1
  Q92731       Estrogen receptor beta                                                                                 ESR2
  P00742       Coagulation factor Xa                                                                                  F10
  P00734       Thrombin                                                                                               F2
  P08709       Coagulation factor VII                                                                                 F7
  P07148       Fatty acid-binding protein, liver                                                                      FABP1
  P01100       Proto-oncogene c-Fos                                                                                   FOS
  P15408       Fos-related antigen 2                                                                                  FOSL2
  P35575       Glucose-6-phosphatase                                                                                  G6PC
  P14867       Gamma-aminobutyric acid receptor subunit alpha-1                                                       GABRA1
  P47869       Gamma-aminobutyric-acid receptor alpha-2 subunit                                                       GABRA2
  P34903       Gamma-aminobutyric-acid receptor alpha-3 subunit                                                       GABRA3
  P48169       Gamma-aminobutyric-acid receptor subunit alpha-4                                                       GABRA4
  P31644       Gamma-aminobutyric-acid receptor alpha-5 subunit                                                       GABRA5
  Q16445       Gamma-aminobutyric-acid receptor subunit alpha-6                                                       GABRA6
  P17677       Neuromodulin                                                                                           GAP43
  P47871       Glucagon                                                                                               GCGR
  P14136       Glial fibrillary acidic protein                                                                        GFAP
  Q2TU84       Growth-inhibiting protein 18                                                                           GIG18
  P23415       Glycine receptor alpha-1 chain                                                                         GLRA1
  P00367       Glutamate dehydrogenase 1, mitochondrial                                                               GLUD1
  P17174       Aspartate aminotransferase, cytoplasmic                                                                GOT1
  P00505       Aspartate aminotransferase, mitochondrial                                                              GOT2
  P42262       Glutamate receptor 2                                                                                   GRIA2
  P49841       Glycogen synthase kinase-3 beta                                                                        GSK3B
  Q15486       Putative beta-glucuronidase-like protein SMA3                                                          GUSBP1
  P19367       Hexokinase-1                                                                                           HK1
  P04035       3-hydroxy-3-methylglutaryl-coenzyme A reductase                                                        HMGCR
  P00738       Haptoglobin                                                                                            HP
  O14756       Oxidoreductase                                                                                         HSD17B6
  P08238       Heat shock protein HSP 90                                                                              HSP90AB1
  P28223       5-hydroxytryptamine 2A receptor                                                                        HTR2A
  P01344       Insulin-like growth factor II                                                                          IGF2
  P01857       Ig gamma-1 chain C region                                                                              IGHG1
  P22301       Interleukin-10                                                                                         IL10
  P05231       Interleukin-6                                                                                          IL6
  P01308       Insulin                                                                                                INS
  Q12809       Potassium voltage-gated channel subfamily H member 2                                                   KCNH2
  Q12791       Calcium-activated potassium channel subunit alpha 1                                                    KCNMA1
  P35968       Vascular endothelial growth factor receptor 2                                                          KDR
  P09848       Lactase-phlorizin hydrolase                                                                            LCT
  Q32P28       Prolyl 3-hydroxylase 1                                                                                 LEPRE1
  Q8IVL6       Prolyl 3-hydroxylase 3                                                                                 LEPREL2
  P06858       Lipoprotein lipase                                                                                     LPL
  P09960       Leukotriene A-4 hydrolase                                                                              LTA4H
  P21397       Amine oxidase \[flavin-containing\] A                                                                  MAOA
  P27338       Amine oxidase \[flavin-containing\] B                                                                  MAOB
  Q16539       Mitogen-activated protein kinase 14                                                                    MAPK14
  Q00266       S-adenosylmethionine synthetase isoform type-1                                                         MAT1A
  P31153       S-adenosylmethionine synthetase isoform type-2                                                         MAT2A
  P23368       NAD-dependent malic enzyme, mitochondrial                                                              ME2
  Q16798       NADP-dependent malic enzyme, mitochondrial                                                             ME3
  Q3SYC2       2-acylglycerol O-acyltransferase 2                                                                     MOGAT2
  P05164       Myeloperoxidase                                                                                        MPO
  Q15788       Nuclear receptor coactivator 1                                                                         NCOA1
  Q15596       Nuclear receptor coactivator 2                                                                         NCOA2
  P29475       Nitric-oxide synthase, brain                                                                           NOS1
  P35228       Nitric oxide synthase, inducible                                                                       NOS2
  P29474       Nitric oxide synthase, endothelial                                                                     NOS3
  P16083       NRH dehydrogenase \[quinone\] 2                                                                        NQO2
  Q14994       Nuclear receptor subfamily 1 group I member 3                                                          NR1I3
  P04150       Glucocorticoid receptor                                                                                NR3C1
  P08235       Mineralocorticoid receptor                                                                             NR3C2
  Q16620       BDNF/NT-3 growth factors receptor                                                                      NTRK2
  P04181       Ornithine aminotransferase, mitochondrial                                                              OAT
  P00480       Ornithine carbamoyltransferase, mitochondrial                                                          OTC
  Q9BYC2       Succinyl-CoA:3-ketoacid-coenzyme A transferase 2, mitochondrial                                        OXCT2
  O15460       Prolyl 4-hydroxylase subunit alpha-2                                                                   P4HA2
  P49585       Choline-phosphate cytidylyltransferase A                                                               PCYT1A
  Q14432       CGMP-inhibited 3′,5′-cyclic phosphodiesterase A                                                        PDE3A
  O00330       Pyruvate dehydrogenase protein X component, mitochondrial                                              PDHX
  P52945       Pancreas/duodenum homeobox protein 1                                                                   PDX1
  P06401       Progesterone receptor                                                                                  PGR
  P48736       Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform                        PIK3CG
  P11309       Proto-oncogene serine/threonine-protein kinase Pim-1                                                   PIM1
  P61925       cAMP-dependent protein kinase inhibitor alpha                                                          PKIA
  P14618       Pyruvate kinase isozymes M1/M2                                                                         PKM2
  P04054       Phospholipase A2                                                                                       PLA2G1B
  P00749       Urokinase-type plasminogen activator                                                                   PLAU
  P00747       Plasminogen                                                                                            PLG
  P00491       Purine nucleoside phosphorylase                                                                        PNP
  P27169       Serum paraoxonase/arylesterase 1                                                                       PON1
  Q07869       Peroxisome proliferator-activated receptor alpha                                                       PPARA
  Q03181       Peroxisome proliferator-activated receptor delta                                                       PPARD
  P37231       Peroxisome proliferator activated receptor gamma                                                       PPARG
  Q9UBK2       Peroxisome proliferator-activated receptor gamma coactivator 1-alpha                                   PPARGC1A
  P17612       mRNA of PKA Catalytic Subunit C-alpha                                                                  PRKACA
  P05771       Protein kinase C beta type                                                                             PRKCB
  P35030       Trypsin-3                                                                                              PRSS3
  P60484       Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN   PTEN
  P43115       Prostaglandin E2 receptor EP3 subtype                                                                  PTGER3
  P23219       Prostaglandin G/H synthase 1                                                                           PTGS1
  P35354       Prostaglandin G/H synthase 2                                                                           PTGS2
  P18031       mRNA of Protein-tyrosine phosphatase, non-receptor type 1                                              PTPN1
  P10082       Peptide YY                                                                                             PYY
  P63000       Ras-related C3 botulinum toxin substrate 1                                                             RAC1
  P50120       Retinol-binding protein 2                                                                              RBP2
  P08100       Rhodopsin                                                                                              RHO
  P19793       Retinoic acid receptor RXR-alpha                                                                       RXRA
  O00767       Acyl-CoA desaturase                                                                                    SCD
  Q14524       Sodium channel protein type 5 subunit alpha                                                            SCN5A
  P31040       Succinate dehydrogenase \[ubiquinone\] flavoprotein subunit, mitochondrial                             SDHA
  P16109       P-selectin                                                                                             SELP
  P05121       Plasminogen activator inhibitor 1                                                                      SERPINE1
  P14410       Sucrase-isomaltase, intestinal                                                                         SI
  O76082       Solute carrier family 22 member 5                                                                      SLC22A5
  Q9UBX3       Mitochondrial dicarboxylate carrier                                                                    SLC25A10
  P11168       Solute carrier family 2, facilitated glucose transporter member 2                                      SLC2A2
  P23975       Sodium-dependent noradrenaline transporter                                                             SLC6A2
  Q01959       Sodium-dependent dopamine transporter                                                                  SLC6A3
  P31645       Sodium-dependent serotonin transporter                                                                 SLC6A4
  P35610       Sterol O-acyltransferase 1                                                                             SOAT1
  P00441       Superoxide dismutase \[Cu-Zn\]                                                                         SOD1
  P08047       Transcription factor Sp1                                                                               SP1
  P12931       Proto-oncogene tyrosine-protein kinase SRC                                                             SRC
  P36956       Sterol regulatory element-binding protein 1                                                            SREBF1
  Q12772       Sterol regulatory element-binding protein 2                                                            SREBF2
  Q9P2R7       Succinyl-CoA ligase \[ADP-forming\] beta-chain, mitochondrial                                          SUCLA2
  Q99973       Telomerase protein component 1                                                                         TEP1
  P01375       Tumor necrosis factor                                                                                  TNF
  Q16881       Thioredoxin reductase, cytoplasmic                                                                     TXNRD1
  P55851       Mitochondrial uncoupling protein 2                                                                     UCP2
  P55916       Mitochondrial uncoupling protein 3                                                                     UCP3
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